Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + MET mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EGFR exon 19 deletion (79)

MET amplification (66)

EGFR amplification (52)

EGFR exon 18 deletion (3)

MET exon 14 deletion (3)

EGFR exon 2-7 deletion + EGFR amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

EGFR exon 21 deletion (1)

HER-2 amplification + MET amplification (1)

MET amplification + AXL amplification (1)

EGFR T790M + exon 19 deletion (0)

EGFR amplifcation (0)

EGFR exon 19 deletion (79)

MET amplification (66)

EGFR amplification (52)

EGFR exon 18 deletion (3)

MET exon 14 deletion (3)

EGFR exon 2-7 deletion + EGFR amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

EGFR exon 21 deletion (1)

HER-2 amplification + MET amplification (1)

MET amplification + AXL amplification (1)

EGFR T790M + exon 19 deletion (0)

EGFR amplifcation (0)

›

EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3